The prevalence of chronic pain associated with numerous indications (e.g., osteoarthritis, cancer) and of idiopathic origin (e.g., chronic back pain) continues to increase throughout the EU5. The mature prescription analgesic landscape, while crowded with many well-established treatment options, nevertheless presents commercial opportunities for drug developers because treatment of refractory chronic pain remains a challenge. However, new therapies will need to compete for positioning in an already-complex treatment algorithm, and a growing generic presence across multiple drug classes—coupled with evolving access and reimbursement requirements throughout the EU5—will result in increasing market access challenges for branded therapies.
- Chronic Pain - Access & Reimbursement - Detailed, Expanded Analysis (EU5)
Author(s): Joyce Spadafora, ALM
Joyce is a business insights analyst in Decision Resources Group’s central nervous systems and ophthalmology division, where she provides expert insight into commercial aspects of drug development and market sizing across psychiatric and pain indications. She has worked extensively in DRG’s schizophrenia and chronic pain content.
Prior to joining DRG, Joyce spent several years in the biotech industry focused in research and development and in biotech consulting. Her project experience covered indications including psychiatry, pain, infectious diseases, respiratory, and ophthalmology. Beyond my therapeutic and industry knowledge, she holds a Masters in Extension Studies in Psychology from Harvard University and a B.S in Mechanical Engineering with Biology from the Massachusetts Institute of Technology.